Is there a distinction between the 1-size-fits-all approach and personalized medicine? David C. Collymore, MD, MBA, is certain there is.
“Medicine in general has evolved over time and 1-size-fits-all is an evidence-based approach that affects the population in general. While there has been a tremendous benefit to that over time, we have realized now that no 2 people are the same—this is not just with respect to expression of specific genes, but even differences based on ethnicities—realizing that certain medications may be more effective in specific populations.”
Dr Collymore explained that personalized medicine is definitely the next step and there have been enough scientific advances to prove the utility and cost effectiveness of the approach. “One-size-fits-all is the initial step and to get to the next step of quality of care and to ensure that we are providing the most effective treatment, for that individual, at that time, is what really makes sense,” said Dr Collymore.
While population health will remain a major focus of healthcare to treat disease processes and to improve overall outcomes, Dr Collymore thinks that personalized medicine will lead us to a more advanced stage of healthcare. “The biggest concern for everyone is ‘Am I at risk for a certain type of cancer?’ Personalized medicine—maybe not today—can get to a point where it can answer that question for a large percentage of our population,” he said.
Citing the example of a study that identified a reduced risk of colon cancer in individuals who took daily aspirin, Dr Collymore hypothesized that a personalized approach could help avoid gastrointestinal side effects of aspirin while reducing the risk of developing cancer. “The personalized approach to medicine and healthcare is in development. Despite great strides there is a lot more work to do to show effectiveness at the screening level as well as the treatment level,” he added.
The 1-size-fits-all approach is quickly becoming an antiquated model of thinking, and without the personalized approach, we would be decades behind in terms of treatment. According to Dr Collymore, if we get to a point in breast cancer care, for example, where the incidence of breast cancer or the incidence of treatment of breast cancer is significantly reduced because of personalized medicine, over time we’ll be able to see the impact on our entire healthcare landscape.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Data Show Undocumented Latinx People Face Disproportionate Burden of Long COVID
October 17th 2024New findings show that undocumented Latinx immigrants, who make up 7% of the US population, face significant challenges in accessing health care due to uninsurance, limited access to care, language barriers, and fears surrounding their immigration status.
Read More